Mehdi Hadadzadeh

Mehdi Hadadzadeh

Auto-generated profile, based on publicly available information

Mehdi Hadadzadeh

Department of Cardiac Surgery, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2020 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
FMFatemeh Sadat Mirfakhradini
Fatemeh Sadat Mirfakhradini
FTFahime Tayefi
Fahime Tayefi
SGSaghar Ghorbani
Saghar Ghorbani
MKMehri Khatami
Mehri Khatami
MHMehdi Hadadzadeh
Mehdi Hadadzadeh

13 September 2019 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
SDSima Dianatpour
Sima Dianatpour
MKMehri Khatami
Mehri Khatami
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
MHMehdi Hadadzadeh
Mehdi Hadadzadeh

5 September 2020 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
MMMonireh Mohammadpanah
Monireh Mohammadpanah
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
MKMehri Khatami
Mehri Khatami
MHMehdi Hadadzadeh
Mehdi Hadadzadeh
Introduction: Atherosclerosis is the important cause of most cardiovascular diseases, with high prevalence and mortality. Atherosclerosis is not only a lipid metabolism disorder but also recently is defined as a chronic inflammatory disease. Several studies showed that interleukin-6 (IL-6) is involved in the pathogenesis of atherosclerosis. The aim of the present study is the examination of IL6 mRNA Levels and hypomethylation of IL6 promoter in atherosclerosis patients. Methods: In this assay, a total of 35 cases with atherosclerosis and 30 controls were enrolled. RNA and DNA were isolated from the peripheral blood of all samples. Mean IL6 gene expression was determined by RT-PCR and methylation status at six CpG motifs in IL6 promoter was determined using bisulfite genomic sequencing. Results: Real Time-PCR analysis results showed the mean IL6 RNA level in atherosclerosis patients candidate for CABG (coronary artery bypass grafting) was significantly higher than controls (P value = 0.01). Also, the upstream CpG motifs (-1038 to -952) in IL6 promoter were predominantly unmethylated in patients than in the controls (P value = 0.01). Conclusion: These findings suggest that an increase in IL-6 gene expression and its DNA hypomethylation promoter are associated with atherosclerosis patient’s candidate for CABG surgery.


3 November 2022 in EXCLI Journal
Verified
Journal Article
Open access
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
MKMehri Khatami
Mehri Khatami
AKAkram Kamalipour
Akram Kamalipour
MKMustafa Kalantari
Mustafa Kalantari
MMMahsa Movahed
Mahsa Movahed
BMBahareh Mazrouei
Bahareh Mazrouei
Most studies aiming at unraveling the molecular events associated with cardiac congenital heart disease (CHD) have focused on the effect of mutations occurring in the nuclear genome. In recent years, a significant role has been attributed to mitochondria for correct heart development and maturation of cardiomyocytes. Moreover, numerous heart defects have been associated with nucleotide variations occurring in the mitochondrial genome, affecting mitochondrial functions and cardiac energy metabolism, including genes encoding for subunits of respiratory chain complexes. Therefore, mutations in the mitochondrial genome may be a major cause of heart disease, including CHD, and their identification and characterization can shed light on pathological mechanisms occurring during heart development. Here, we have analyzed mitochondrial genetic variants in previously reported mutational genome hotspots and the flanking regions of mt-ND1, mt-ND2, mt-COXI, mt-COXII, mt-ATPase8, mt-ATPase6, mt-COXIII, and mt-tRNAs (Ile, Gln, Met, Trp, Ala, Asn, Cys, Tyr, Ser, Asp, and Lys) encoding genes by polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP) in 200 patients with CHD, undergoing cardiac surgery. A total of 23 mitochondrial variations (5 missense mutations, 8 synonymous variations, and 10 nucleotide changes in tRNA encoding genes) were identified and included 16 novel variants. Additionally, we showed that intracellular ATP was significantly reduced (P=0.002) in CHD patients compared with healthy controls, suggesting that the mutations have an impact on mitochondrial energy production. Functional and structural alterations caused by the mitochondrial nucleotide variations in the gene products were studied in-silico and predicted to convey a predisposing risk factor for CHD. Further studies are necessary to better understand the mechanisms by which the alterations identified in the present study contribute to the development of CHD in patients.

13 July 2023 in Gene Reports
Verified
Journal Article
Closed access
MKMehri Khatami
Mehri Khatami
DGDonya Ghazinader
Donya Ghazinader
FAFatemeh Ahmadi
Fatemeh Ahmadi
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
MHMehdi Hadadzadeh
Mehdi Hadadzadeh
MNMohsen Namnabat
Mohsen Namnabat